Naohisa Yahagi

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Motohiko Kato · 4 shared papers, 2023–2025 · strength 0.82
   • Paper Stromal modifying CHST15 siRNA enhances antitumor effect synergistically with anti-PD-1 immune checkpoint antibody in m… DOI 10.1038/s41598-025-09445-6↗
   • Paper Intra-tumoral administration of CHST15 siRNA remodels tumor microenvironment and augments tumor-infiltrating T cells in… DOI 10.1016/j.omton.2024.200812↗
   • Paper Silencing of tumoral carbohydrate sulfotransferase 15 reactivates lymph node pancreatic cancer T cells in mice. DOI 10.1002/eji.202250160↗
2. Keiko Yamakawa · 3 shared papers, 2023–2025 · strength 0.66
   • Paper Stromal modifying CHST15 siRNA enhances antitumor effect synergistically with anti-PD-1 immune checkpoint antibody in m… DOI 10.1038/s41598-025-09445-6↗
   • Paper Intra-tumoral administration of CHST15 siRNA remodels tumor microenvironment and augments tumor-infiltrating T cells in… DOI 10.1016/j.omton.2024.200812↗
   • Paper Silencing of tumoral carbohydrate sulfotransferase 15 reactivates lymph node pancreatic cancer T cells in mice. DOI 10.1002/eji.202250160↗
3. Juanjuan Ye · 3 shared papers, 2023–2025 · strength 0.66
   • Paper Stromal modifying CHST15 siRNA enhances antitumor effect synergistically with anti-PD-1 immune checkpoint antibody in m… DOI 10.1038/s41598-025-09445-6↗
   • Paper Intra-tumoral administration of CHST15 siRNA remodels tumor microenvironment and augments tumor-infiltrating T cells in… DOI 10.1016/j.omton.2024.200812↗
   • Paper Silencing of tumoral carbohydrate sulfotransferase 15 reactivates lymph node pancreatic cancer T cells in mice. DOI 10.1002/eji.202250160↗
4. Akira Nishiyama · 2 shared papers, 2024–2025 · strength 0.46
   • Paper Stromal modifying CHST15 siRNA enhances antitumor effect synergistically with anti-PD-1 immune checkpoint antibody in m… DOI 10.1038/s41598-025-09445-6↗
   • Paper Intra-tumoral administration of CHST15 siRNA remodels tumor microenvironment and augments tumor-infiltrating T cells in… DOI 10.1016/j.omton.2024.200812↗
5. Kyuichi Kadota · 2 shared papers, 2024–2025 · strength 0.46
   • Paper Stromal modifying CHST15 siRNA enhances antitumor effect synergistically with anti-PD-1 immune checkpoint antibody in m… DOI 10.1038/s41598-025-09445-6↗
   • Paper Intra-tumoral administration of CHST15 siRNA remodels tumor microenvironment and augments tumor-infiltrating T cells in… DOI 10.1016/j.omton.2024.200812↗
6. Yoko Matsuda · 3 shared papers, 2018–2023 · strength 0.44
   • Paper Silencing of tumoral carbohydrate sulfotransferase 15 reactivates lymph node pancreatic cancer T cells in mice. DOI 10.1002/eji.202250160↗
   • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
   • Paper Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival… DOI 10.1016/j.gie.2017.10.030↗
7. Kazuki Takakura · 2 shared papers, 2019–2023 · strength 0.27
   • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
   • Paper The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer. DOI 10.3390/ijms20133331↗
8. Makoto Nishimura · 2 shared papers, 2018–2023 · strength 0.24
   • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
   • Paper Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival… DOI 10.1016/j.gie.2017.10.030↗
9. Tomio Arai · 2 shared papers, 2018–2023 · strength 0.24
   • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
   • Paper Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival… DOI 10.1016/j.gie.2017.10.030↗
10. Takao Itoi · 2 shared papers, 2018–2023 · strength 0.24
    • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
    • Paper Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival… DOI 10.1016/j.gie.2017.10.030↗
11. Toshio Fujisawa · 1 shared paper, 2023 · strength 0.16
    • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
12. Hiroyuki Isayama · 1 shared paper, 2023 · strength 0.16
    • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
13. Shomei Ryozawa · 1 shared paper, 2023 · strength 0.16
    • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
14. Hideyuki Saya · 1 shared paper, 2023 · strength 0.16
    • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
15. Yuichi Torisu · 1 shared paper, 2019 · strength 0.11
    • Paper The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer. DOI 10.3390/ijms20133331↗
16. Shigeo Koido · 1 shared paper, 2019 · strength 0.11
    • Paper The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer. DOI 10.3390/ijms20133331↗
17. Masayuki Saruta · 1 shared paper, 2019 · strength 0.11
    • Paper The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer. DOI 10.3390/ijms20133331↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.